|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-12-9
|
|
pubmed:abstractText |
The BRCA2 372 HH genotype defined by the BRCA2 N372H nonconservative amino acid substitution polymorphism was recently reported to be associated with a small increased risk of breast cancer. We investigated whether this polymorphism was associated with ovarian cancer risk by conducting British and Australian case-control comparisons in parallel, including a total sample of 1,121 ovarian cancer cases and 2,643 controls. There was no difference in genotype frequency between control groups from the 2 studies (p = 0.9). The HH genotype was associated with an increased risk of ovarian cancer in both studies, and the risk estimate for the pooled studies was 1.36 (95% CI 1.04-1.77, p = 0.03). There was also a suggestion that this risk may be greater for ovarian cancers of the serous subtype for both studies, with an OR (95% CI) of 1.66 (1.17-2.54) for the 2 studies combined (p = 0.005). The BRCA2 372 HH genotype appears to be associated with an increased risk of ovarian cancer of a similar magnitude to that reported for breast cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0020-7136
|
|
pubmed:author |
pubmed-author:AuranenAnnikaA,
pubmed-author:ChenXiaoqingX,
pubmed-author:Chenevix-TrenchGeorgiaG,
pubmed-author:DunningAlison MAM,
pubmed-author:EastonDouglas FDF,
pubmed-author:GreenAdeleA,
pubmed-author:HealeyCatherine SCS,
pubmed-author:HopperJohn LJL,
pubmed-author:LipscombeJulianJ,
pubmed-author:NovikKaren LKL,
pubmed-author:PharoahPaul DPD,
pubmed-author:PonderBruce A JBA,
pubmed-author:PurdieDavid MDM,
pubmed-author:RedmanKarenK,
pubmed-author:SpurdleAmanda BAB
|
|
pubmed:copyrightInfo |
Copyright 2002 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
427-30
|
|
pubmed:dateRevised |
2007-7-24
|
|
pubmed:meshHeading |
pubmed-meshheading:12471628-Adenocarcinoma, Clear Cell,
pubmed-meshheading:12471628-Adenocarcinoma, Mucinous,
pubmed-meshheading:12471628-Adult,
pubmed-meshheading:12471628-Aged,
pubmed-meshheading:12471628-Aged, 80 and over,
pubmed-meshheading:12471628-BRCA2 Protein,
pubmed-meshheading:12471628-Carcinoma, Endometrioid,
pubmed-meshheading:12471628-Case-Control Studies,
pubmed-meshheading:12471628-Cystadenocarcinoma, Serous,
pubmed-meshheading:12471628-DNA Mutational Analysis,
pubmed-meshheading:12471628-Female,
pubmed-meshheading:12471628-Genotype,
pubmed-meshheading:12471628-Humans,
pubmed-meshheading:12471628-Middle Aged,
pubmed-meshheading:12471628-Neoplasm Invasiveness,
pubmed-meshheading:12471628-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:12471628-Ovarian Neoplasms,
pubmed-meshheading:12471628-Polymorphism, Genetic,
pubmed-meshheading:12471628-Risk Factors
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
BRCA2 Arg372Hispolymorphism and epithelial ovarian cancer risk.
|
|
pubmed:affiliation |
CRC Department of Oncology, Strangeways Research Laboratory, Cambridge, UK.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
